Tapewire

Nasdaq · USD

COLL

COLLEGIUM PHARMACEUTICAL, INC

Export transactions ↓
Tapewire entity
5169
SEC CIK
0001267565
Parsed reports
359

Last 12 months

Inside the activity.

0 purchase rows · 14 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202503
Dec 202503
Jan 202600
Feb 202600
Mar 202604
Apr 202600
May 202604
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
March 17, 2017 Filed Mar 21, 2017 20:45 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
Tax withholdingCommon Stock 1,472 $14.95 $22,006.40
Disclosure

SEC source: 0001192482-17-000088 · edgar.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 609,083

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
March 17, 2017 Filed Mar 21, 2017 20:44 UTC
Brannelly PaulExecutive Vice President & CFO
Tax withholdingCommon Stock 388 $14.95 $5,800.60
Disclosure

SEC source: 0001192482-17-000087 · edgar.xml · nonDerivative · entry 1

Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,227

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 17:54 UTC
Duke Barry SSee remarks
GrantStock Option (Right to Purchase) · Derivative 27,500 $0.00 Strike: $15.27 $0.00
Disclosure

SEC source: 0001192482-17-000040 · edgar.xml · derivative · entry 3

Duke Barry S · CIK 0001640699 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2027-02-10

F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 17:54 UTC
Duke Barry SSee remarks
GrantCommon Stock 13,750 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000040 · edgar.xml · nonDerivative · entry 2

Duke Barry S · CIK 0001640699 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 17:56 UTC
Fleming Alison BChief Technology Officer
GrantStock Option (Right to Purchase) · Derivative 32,500 $0.00 Strike: $15.27 $0.00
Disclosure

SEC source: 0001192482-17-000042 · edgar.xml · derivative · entry 3

Fleming Alison B · CIK 0001640701 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2027-02-10

F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 17:56 UTC
Fleming Alison BChief Technology Officer
GrantCommon Stock 16,250 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000042 · edgar.xml · nonDerivative · entry 2

Fleming Alison B · CIK 0001640701 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,701

F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:54 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
GrantStock Option (Right to Purchase) · Derivative 110,000 $0.00 Strike: $15.27 $0.00
Disclosure

SEC source: 0001192482-17-000041 · edgar.xml · derivative · entry 2

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2027-02-10

F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:54 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
GrantCommon Stock 55,000 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000041 · edgar.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,555

F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:53 UTC
Brannelly PaulExecutive Vice President & CFO
GrantStock Option (Right to Purchase) · Derivative 32,500 $0.00 Strike: $15.27 $0.00
Disclosure

SEC source: 0001192482-17-000039 · edgar.xml · derivative · entry 3

Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2027-02-10

F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.

Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:53 UTC
Brannelly PaulExecutive Vice President & CFO
GrantCommon Stock 16,250 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 2

Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,615

F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.

Read SEC document
January 31, 2017 Filed Feb 2, 2017 21:26 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
Exercise / conversionStock Option (Right to Purchase) · Derivative 3,013 $0.00 Strike: $0.48 $0.00
Disclosure

SEC source: 0001192482-17-000027 · edgar.xml · derivative · entry 3

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,013 shares

Expires 2023-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All of the 3,013 option shares are exercisable.

Read SEC document
January 31, 2017 Filed Feb 2, 2017 21:26 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
Exercise / conversionCommon Stock 3,013 $0.48 $1,446.24
Disclosure

SEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 2

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 555,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 27, 2017 Filed Feb 2, 2017 21:26 UTC
Heffernan Michael ThomasDirector · Chairman, President and CEO
GrantCommon Stock 1,239 $10.08 $12,489.12
Disclosure

SEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 552,542

F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
January 27, 2017 Filed Feb 14, 2017 17:54 UTC
Duke Barry SSee remarks
GrantCommon Stock 834 $10.08 $8,406.72
Disclosure

SEC source: 0001192482-17-000040 · edgar.xml · nonDerivative · entry 1

Duke Barry S · CIK 0001640699 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,725

F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
January 27, 2017 Filed Feb 14, 2017 17:56 UTC
Fleming Alison BChief Technology Officer
GrantCommon Stock 1,240 $10.08 $12,499.20
Disclosure

SEC source: 0001192482-17-000042 · edgar.xml · nonDerivative · entry 1

Fleming Alison B · CIK 0001640701 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,451

F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
January 27, 2017 Filed Feb 14, 2017 22:53 UTC
Brannelly PaulExecutive Vice President & CFO
GrantCommon Stock 1,006 $10.08 $10,140.48
Disclosure

SEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 1

Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,365

F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.